<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04395027</url>
  </required_header>
  <id_info>
    <org_study_id>13708</org_study_id>
    <nct_id>NCT04395027</nct_id>
  </id_info>
  <brief_title>Iatrogenic Atrial Septal Defect Study (iASD)</brief_title>
  <acronym>iASD</acronym>
  <official_title>Iatrogenic Atrial Septal Defect Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, controlled trial of iatrogenic atrial septal defect
      closure with the an atrial septal occluder versus usual care observation in patients
      post-mitral valve intervention requiring large bore transspetal access.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open label, prospective, multicenter, non-randomized single-arm study to
      evaluate the safety and efficacy of the closing iatrogenic atrial septal defects in patients
      undergoing transcatheter mitral valve procedures using large sheaths.

      A maximum of 5 Clinical Sites (referred to as &quot;Sites&quot; in the remainder of this document) in
      the U.S. Two hundred and ten patients will be enrolled in this study. The patients will
      randomized 1:2 device: control. The anticipated accrual rate is approximately 20 Subjects per
      month for a total accrual period of approximately 12-18 months.

      Patients may be enrolled into the study provided all inclusion and no exclusion criteria are
      met as specified in Section 4. Subjects will be evaluated through hospital discharge and
      return for follow-up visits at 30 days, 6 months, and 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2020</start_date>
  <completion_date type="Anticipated">May 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 6, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival</measure>
    <time_frame>6 month</time_frame>
    <description>Survival at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>1 year</time_frame>
    <description>survival at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom forheart failure hospitalization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from heart failure hospitalization</measure>
    <time_frame>1 year</time_frame>
    <description>Heart failure hospitalizations at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>1 year</time_frame>
    <description>Symptom status at 1 year</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Septal Defect, Atrial</condition>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>These patients will not have their iatrogenic septal defect closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These patients will have their iatrogenic septal defect closed after the mitral intervention is completed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>atrial septal defect closure</intervention_name>
    <description>The iatrogenic septal defect will be closed in the usual manner</description>
    <arm_group_label>Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 at the time of informed consent signature.

          2. Capable of complying with Protocol requirements, including follow-up.

          3. An Informed Consent Form signed by Subject or legal representative.

          4. Patient has had successful reduction of mitral regurgitation to at most moderate
             regurgitation post-mitral-clip.

        Exclusion Criteria:

          1. Remaining mitral regurgitation of ≥ moderate-severe

          2. Subject unable or unwilling to provide informed consent

          3. Concomitant severe aortic valve disease

          4. Dialysis

          5. Pregnancy or intent to become pregnant

          6. Life expectancy &lt; 1 year

          7. Active bleeding

          8. Inability to follow up with 6-month timepoint due logistical concerns
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marvin Eng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marvin Eng</last_name>
    <phone>3132075515</phone>
    <phone_ext>3132075515</phone_ext>
    <email>meng1@hfhs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kacorri, Ardit</last_name>
    <phone>3139167452</phone>
    <phone_ext>3139167452</phone_ext>
    <email>akacorr1@hfhs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Marvin Eng</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marvin Eng</last_name>
      <phone>313-207-5515</phone>
      <phone_ext>3132075515</phone_ext>
      <email>meng1@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Kacorri, Ardit</last_name>
      <phone>3139167452</phone>
      <phone_ext>3139167452</phone_ext>
      <email>akacorr1@hfhs.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 15, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Marvin Eng</investigator_full_name>
    <investigator_title>Senior Staff</investigator_title>
  </responsible_party>
  <keyword>mitral valve intervention</keyword>
  <keyword>iatrogenic septal defect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Septal Defects</mesh_term>
    <mesh_term>Heart Septal Defects, Atrial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

